Company: CSCIF
Filing Date: 2025-04-09
Form Type: 20-F
Source: 0001641172-25-003456
Chunk: 57

Company: COSCIENS Biopharma Inc.
Filing Date: 2025-04-09
Form: 20-F
Item: Item 5
Chunk 57
---
MA Code on Interactions with Healthcare Professionals and
PhRMA Guiding Principles Direct to Consumer Advertisements About Prescription Medicines) and rigorous internal training and compliance
efforts will complement existing laws and regulations to help ensure ethical collaboration and truthful product communications.

The Canadian Association of Research-Based Pharmaceutical
Companies (“Rx & D”), now Innovative Medicines Canada, has adopted “ Guidelines for Transparency in Stakeholder Funding” that require
member companies to regularly disclose, by means of websites and annual reports, a list of all stakeholders to which they provide direct
funding. The term “stakeholder” is defined in Rx & D’s Code of Ethical Practices to include “ Health Care
Professionals”. In the EU, the disclosure code of transfers of value to healthcare professionals and organizations adopted by the
European Federation of Pharmaceutical Industries and Associations (“EFPIA”) requires all members of EFPIA to disclose
transfers of value to healthcare professionals and healthcare organizations beginning in 2016, covering the relevant transfers in 2015.
Each member company will be required to document and disclose: (i) the names of healthcare professionals and associations that have received
payments or other transfers of value and (ii) the amounts or value transferred, and the type of relationship.

For more information about the regulatory risks associated
with our business operations, see “ Item 3D. Risk Factors”.

Environmental Protection

The operations of the Company are subject to a variety
of federal, provincial and local laws, regulations and guidelines, including various environmental and health and safety regulations,
regulating the conduct of its operations, the requirements for its products, the protection of the environment, the operation of its
equipment and the handling and disposal of substances used in its operations. The Company believes that it is currently in compliance
with such laws and regulations. Such laws or regulations are subject to change. Accordingly, it is impossible for the Company to predict
the cost or impact of such laws and regulations on the Company’s future operations.

Intellectual Property - Patents

We seek to protect our compounds, manufacturing processes,
compositions and methods of medical use for our lead drugs and drug candidates through a combination of patents, trade secrets and know-how.
Our patent portfolio consists of approximately six owned and in-licensed patent families (issued, granted or pending in the U. S., Europe
and other jurisdictions). The patent positions of companies in the biotechnology and pharmaceutical industries are highly uncertain and
involve complex legal and factual questions. Therefore, we cannot predict the